日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
Lifestyle
Home / Lifestyle / Health

Transparency needed for oversight of vaccine-makers

By Wang Xiaoyu | China Daily | Updated: 2018-11-22 10:25
Share
Share - WeChat

Experts called for more transparency in vaccine supervision after China's drug regulator disclosed on Tuesday that it had denied market access for more than 100,000 doses of rabies vaccine produced by two manufacturers in Jilin province.

Some 43,510 doses from Maifeng Bio Tech Co failed premarket checks of safety and effectiveness on Oct 29, as did 57,290 doses from Zhuoyi Biological Co on Nov 5. Both manufacturers are based in Changchun, Jilin.

The checks were conducted by the National Institutes for Food and Drug Control, which released the information about the substandard vaccines on its website.

Also in October, the authority denied market access to 77,516 doses of a rabies vaccine made by Chengda Biotech in Shenyang, Liaoning province.

Wang Yuedan, a professor at Peking University Health Science Center's immunology school, said rising public concern about vaccine quality prompted the regulator to release more information on substandard products.

"The latest disclosure of market denial is not directly linked to stricter vaccine management. It's more of an answer to public demand for more information on the production and supervision of rabies vaccines," he said.

Zeng Guang, an epidemiologist at China's Center for Disease Control and Prevention, said it's crucial to promote dialogue between the drug regulator, vaccine manufacturers and the public.

"Manufacturers should be notified of their products' problems to improve production," he said. "And the public is also entitled to be aware of quality issues."

While the notice didn't say why market access was denied, Wang said, the reasons are most likely associated with low effectiveness or excessive levels of contaminants in the drugs.

"China is a huge market for rabies vaccines, and many manufacturers tap into the market," he said. "Not all producers hold themselves to high standards."

China has been rolling out new measures to tighten its supervision of vaccine-makers following a major quality scandal that involved Changchun Changsheng Bio-tech Co, a large producer found to have made substandard vaccines.

The National Medical Products Administration pledged early this month to prioritize building an online tracking system for vaccines, anesthetics and psychoactive drugs to ensure their safety.

On Nov 12, a draft vaccine law was released by the State Administration for Market Regulation for public feedback. If approved, companies that make illegal or substandard vaccines could face fines of up to 10 times the value of the products.

?

Most Popular
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 日韩a| 国产免费久久精品44 | 精品一区二区国语对白 | av一区在线观看 | 色黄网站在线观看 | 日本中文字幕一区 | 国产一区二区 | 亚洲一本 | 97se亚洲综合在线韩国专区福利 | 亚洲九九夜夜 | 成人国产精品视频 | 亚洲午夜成激人情在线影院 | 国产视频aaa | 久久久久久亚洲 | 亚洲第一页在线播放 | 精品欧美一区二区三区久久久 | 国产最新精品 | 国产手机精品一区二区 | 成年网址网站在线观看 | 天天做天天爱天天大综合 | 日韩精品成人a在线观看 | 亚洲精品综合 | 国产一区二区三区在线 | 免费三级pq | 久久草在线精品视频99 | 美女国内精品自产拍在线播放 | 美女视频黄a视频免费全过程 | 九九99国产精品视频 | 久久成人18免费网站 | 日本成人在线看 | 日韩视频一 | 精品自拍视频 | 99久久产在线 | 久久久精品中文字幕 | 8mav福利视频在线播放 | 亚洲精品www | 日韩免费视频 | 国产色婷婷精品综合在线观看 | 韩国久久久久无码国产精品 | 美女91视频 | 亚洲电影在线观看 |